Oramed Pharmaceuticals
ORMP
26 hedge funds and large institutions have $1.78M invested in Oramed Pharmaceuticals in 2015 Q4 according to their latest regulatory filings, with 12 funds opening new positions, 3 increasing their positions, 4 reducing their positions, and 5 closing their positions.
140% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 5
117% more call options, than puts
Call options by funds: $358K | Put options by funds: $165K
109% more capital invested
Capital invested by funds: $855K → $1.78M (+$928K)
37% more funds holding
Funds holding: 19 → 26 (+7)
25% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Barclays
London,
United Kingdom
|
+$227K |
| 2 |
Group One Trading
Chicago,
Illinois
|
+$135K |
| 3 |
Millennium Management
New York
|
+$109K |
| 4 |
TAM
Tocqueville Asset Management
New York
|
+$75.8K |
| 5 |
Simplex Trading
Chicago,
Illinois
|
+$24.1K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$83.2K |
| 2 |
SM
Sabby Management
Miami Beach,
Florida
|
-$58K |
| 3 |
GIM
Greylin Investment Management
Orange,
Virginia
|
-$58K |
| 4 |
Bank of America
Charlotte,
North Carolina
|
-$37.9K |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$29K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
SM
26
Sabby Management
Miami Beach,
Florida
| – | -$58K | -10,558 | Closed |
|
|
27
Citadel Advisors
Miami,
Florida
| – | -$29K | -5,236 | Closed |
|
|
DLHL
28
Donald L. Hagan LLC
Sarasota,
Florida
| – | -$5K | -1,000 | Closed |
|
|
PSI
29
Pinnacle Summer Investments
Fairfax,
Virginia
| – | +$303 | +40 | New |
|
30
Deutsche Bank
Frankfurt Am Main Ge,
Germany
| – | +$720 | +95 | New |
|
ORMP Hedge Fund Activity: Q4 2015 in Review
26 of the 3,812 institutional investors tracked by Wall St. Rank reported a position in Oramed Pharmaceuticals (ORMP) for Q4 2015, worth a combined $1.78M — up 109% from $855K a quarter earlier.
Buyers outnumbered sellers: 12 funds opened new ORMP positions and 5 closed out — a net gain of 7 holders — while 3 added to existing stakes and 4 trimmed.
The largest buyer was Barclays, opening a new position worth an estimated $227K. The largest seller was Susquehanna International Group, exiting entirely with an estimated $83.2K sold.
- 26 institutional investors held Oramed Pharmaceuticals (ORMP) as of Q4 2015, up from 19 in Q3 2015.
- Funds reported $1.78M of Oramed Pharmaceuticals stock for Q4 2015, up 109% quarter-over-quarter.
- 12 funds opened new Oramed Pharmaceuticals positions in Q4 2015 and 5 closed out, a net change of +7 holders.
- The largest Oramed Pharmaceuticals buyer in Q4 2015 was Barclays, an estimated $227K added.
- The largest Oramed Pharmaceuticals seller in Q4 2015 was Susquehanna International Group, an estimated $83.2K sold.
Based on aggregated 13F filings for Q4 2015.